Today: September 13, 2024
Today: September 13, 2024

Latest From Ludwig Burger

Health|Science

Sanofi's mixed fortunes in MS drug trials has market focus on win

Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive

Sanofi's mixed fortunes in MS drug trials has market focus on win
Business|Finance|Health

Roche lifts 2024 profit guidance on strong drug sales

Roche on Thursday raised its full-year earnings forecast after exceeding expectations for the first half, driven by strong demand for newer drugs such as eye

Roche lifts 2024 profit guidance on strong drug sales
Business|Economy|Europe|Technology

SAP shares at all-time high after adjusted profit beats market view

Shares in SAP rose as much as 7% to reach an all-time high on Tuesday after Europe's largest software maker reported better-than-expected quarterly operating

SAP shares at all-time high after adjusted profit beats market view
Business|Health

Novartis lifts profit forecast for second time on Cosentyx, Entresto

Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including heart failure

Novartis lifts profit forecast for second time on Cosentyx, Entresto
Business|Economy|Technology

Serbia eyes lithium deals with Mercedes, Stellantis, VW, president says

Serbia will give Mercedes-Benz, Volkswagen and Stellantis the opportunity to purchase lithium for car batteries as the nation prioritises European over Chinese

Serbia eyes lithium deals with Mercedes, Stellantis, VW, president says
Health|Science

Bayer eyes wider Nubeqa use on new prostate cancer trial data

Bayer said on Wednesday its Nubeqa drug was shown to slow the progression of a certain type of prostate cancer in a late-stage trial, underpinning growth

Bayer eyes wider Nubeqa use on new prostate cancer trial data
Business

Roche joins race for obesity drugs with $2.7 billion Carmot deal

Roche agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight

Roche joins race for obesity drugs with $2.7 billion Carmot deal
Business

Pfizer, BioNTech shares fall on COVID product sales uncertainty

Shares of Pfizer and German partner BioNTech fell on Monday after the U.S. drugmaker slashed the sales forecast for its COVID vaccine and therapy last week, and some

Pfizer, BioNTech shares fall on COVID product sales uncertainty
Business|Economy

Bayer's first-quarter adjusted profit falls less than expected

Bayer beat first-quarter analyst forecasts as it reported a slight drop in adjusted earnings on Tuesday, providing a respite for the CEO's turnaround efforts.

Bayer's first-quarter adjusted profit falls less than expected
World

Bayer woes pile up as blood thinner drug trial fails

Germany's Bayer has aborted a large late-stage trial testing a new anti-clotting drug due to lack of efficacy, dealing a fresh blow to the embattled drugmaker and throwing

Bayer woes pile up as blood thinner drug trial fails

Follow